STMC 103H
Alternative Names: STMC-103HLatest Information Update: 28 Oct 2023
At a glance
- Originator Siolta Therapeutics
- Class Allergy immunotherapies; Antiallergics; Bacteria
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Atopic dermatitis; Hypersensitivity
- No development reported Allergic asthma; Allergic rhinitis; Food hypersensitivity; Immediate hypersensitivity
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Allergic-asthma in USA (PO)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Allergic-rhinitis in USA (PO)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Atopic-dermatitis in USA (PO, Capsule)